Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood cells, including lymphokine-activated killer cells, to kill tumor cells. Giving cellular adoptive immunotherapy during or after surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well cellular adoptive immunotherapy works in treating patients with glioblastoma multiforme.
Key facts
- Study ID
- NCT00331526
- Run by
- Hoag Memorial Hospital Presbyterian
- People needed
- 83
- Starts
- 1999-02-01
- Expected to finish
- 2012-04-01
- Last updated by the study team
- 2013-03-25
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hoag Cancer Center at Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.